Arylsulfonamido-substituted hydroxamic acid derivatives

Details Arylsulfonamido-substituted hydroxamic acid derivatives Arylsulfonamido-substituted hydroxamic acid derivatives

2006-11-21

2006-11-21

Saeed, Kamel A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Nitrogen containing other than solely as a nitrogen in an...

C514S604000, C564S084000, C564S090000

Reexamination Certificate

active

07138432

ABSTRACT:
α-Amino hydroxamic acid derivative of formula (I), in which R is C2–C7-alkyl, which is mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3–C5-cycloalkyl or unsubstituted or substituted C3–C4-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; or C3–C7-alkenyl or C3–C7-alkynyl, which in each case is unsubstituted or mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3–C5-cycloalkyl or unsubstituted or substituted C3–C6-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; and the other symbols are as defined in claim1, are described. These compounds are MMP and in particular MMP2 inhibitors and can be used for treatment of MMP dependent diseases, in particular inflammation conditions, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or invasi n) and pulmonary disorders (e.g. emphysema, COPD).

REFERENCES:
patent: 2513826 (1950-07-01), Sprung et al.
patent: 5455258 (1995-10-01), MacPherson et al.
patent: 5500337 (1996-03-01), Benard et al.
patent: 5932695 (1999-08-01), Floyd et al.
patent: 5985900 (1999-11-01), Bender et al.
patent: 6150394 (2000-11-01), Watanabe et al.
patent: 6159995 (2000-12-01), Thorwart et al.
patent: 6451824 (2002-09-01), Thorwart et al.
patent: 306453 (1989-03-01), None
patent: 308860 (1989-03-01), None
patent: 469984 (1992-02-01), None
patent: 0877018 (1998-11-01), None
patent: 0877019 (1998-11-01), None
patent: 915086 (1999-05-01), None
patent: 0930067 (1999-07-01), None
patent: 0 950 656 (1999-10-01), None
patent: 0949244 (1999-10-01), None
patent: 2686878 (1993-08-01), None
patent: 11-236369 (1999-09-01), None
patent: WO 96/00214 (1996-01-01), None
patent: 97/44315 (1997-11-01), None
patent: 98/18754 (1998-05-01), None
patent: 98/25597 (1998-06-01), None
patent: WO 98/33768 (1998-08-01), None
patent: 98/47494 (1998-10-01), None
patent: WO 99/06340 (1999-02-01), None
patent: 99/42443 (1999-08-01), None
patent: WO 00/44709 (2000-08-01), None
patent: WO 00/44713 (2000-08-01), None
patent: 01 10827 (2001-02-01), None
patent: 02 064552 (2002-08-01), None
Y. Tamura et al., J. Med. Chem, vol. 41, No. 4, pp. 640-649, XP002151755 (1998).
J. H. Uhlenbroek et al., Recl. Trav. Chim. Pays-Bas, vol. 75, pp. 129-146, XP000953403 (1956).
Scozzafava et al., “Protease Inhibitors: Synthesis of Potent Bacterial Collagenase and Matrix Metalloproteinase Inhibitors Incorporating N-4-nitrobenzylsulphonyglycine Hydroxamate Moieties,” J. Med. Chem., vol. 43, No. 9, pp. 1858-1865 (2000).
MacPherson et al., “Discovery of CGS 27023A, Non-Peptidic, Potent and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits,” J. Med. Chem., vol. 40, pp. 2525-2532 (1997).
Casini et al., “Sulfonamides and sulfonylated derivatives as anticancer agents,” Current Cancer Drug Targets, vol. 2, pp. 55-75, especially p. 58 (2002).
Tamura et al., “Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-Sulfonylamino acid derivatives,” vol. 41, pp. 640-649, especially p. 640. (1998).
Connell et al., “Patent focus on cancer chemotherapeutics. II Angiogenesis agents: Apr. 2000- Sep. 2000,” vol. 11(1), pp. 77-114, especially p. 84 (2001).

Affiliated with

Also associated with

Rating

Arylsulfonamido-substituted hydroxamic acid derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylsulfonamido-substituted hydroxamic acid derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamido-substituted hydroxamic acid derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3655957